BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35008525)

  • 21. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
    Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
    Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
    Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
    Wang XF; Qian DZ; Ren M; Kato Y; Wei Y; Zhang L; Fansler Z; Clark D; Nakanishi O; Pili R
    Clin Cancer Res; 2005 May; 11(9):3535-42. PubMed ID: 15867257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
    Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
    Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetics Involvement in Oxaliplatin-Induced Potassium Channel Transcriptional Downregulation and Hypersensitivity.
    Pereira V; Lamoine S; Cuménal M; Lolignier S; Aissouni Y; Pizzoccaro A; Prival L; Balayssac D; Eschalier A; Bourinet E; Busserolles J
    Mol Neurobiol; 2021 Jul; 58(7):3575-3587. PubMed ID: 33772465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition.
    Shah RD; Jagtap JC; Mruthyunjaya S; Shelke GV; Pujari R; Das G; Shastry P
    J Cell Biochem; 2013 Apr; 114(4):854-63. PubMed ID: 23097134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
    Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
    PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Class I histone deacetylase inhibition modulates metalloproteinase expression and blocks cytokine-induced cartilage degradation.
    Culley KL; Hui W; Barter MJ; Davidson RK; Swingler TE; Destrument AP; Scott JL; Donell ST; Fenwick S; Rowan AD; Young DA; Clark IM
    Arthritis Rheum; 2013 Jul; 65(7):1822-30. PubMed ID: 23575963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
    Kakihana M; Ohira T; Chan D; Webster RB; Kato H; Drabkin HA; Gemmill RM
    J Thorac Oncol; 2009 Dec; 4(12):1455-65. PubMed ID: 20009910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
    Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
    Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventive action of benztropine on platinum-induced peripheral neuropathies and tumor growth.
    Cerles O; Gonçalves TC; Chouzenoux S; Benoit E; Schmitt A; Bennett Saidu NE; Kavian N; Chéreau C; Gobeaux C; Weill B; Coriat R; Nicco C; Batteux F
    Acta Neuropathol Commun; 2019 Jan; 7(1):9. PubMed ID: 30657060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.
    Minami T; Takeda M; Sata M; Kato H; Yano K; Sakai T; Tsujita R; Kawasaki K; Ito A
    Eur J Pharmacol; 2020 Aug; 880():173196. PubMed ID: 32416186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MS-275, a class I histone deacetylase inhibitor, protects the p53-deficient mouse against ischemic injury.
    Murphy SP; Lee RJ; McClean ME; Pemberton HE; Uo T; Morrison RS; Bastian C; Baltan S
    J Neurochem; 2014 May; 129(3):509-15. PubMed ID: 24147654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathological Mechanisms and Preventive Strategies of Oxaliplatin-Induced Peripheral Neuropathy.
    Egashira N
    Front Pain Res (Lausanne); 2021; 2():804260. PubMed ID: 35295491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
    Hui KF; Chiang AK
    Int J Cancer; 2014 Dec; 135(12):2950-61. PubMed ID: 24771510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
    Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
    Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel HDAC1/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell cycle regulation.
    Lee HY; Tang DW; Liu CY; Cho EC
    Chem Biol Interact; 2022 Jan; 352():109778. PubMed ID: 34929181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.